Systemic inflammatory markers as independent prognosticators of head and neck squamous cell Carcinoma

Head and Neck

Volumn 37, Issue 1, 2015, Pages 103-110

  Rassouli, Alipasha ^a   Saliba, Joe ^a   Castano, Roberto ^b   Hier, Michael ^a   Zeitouni, Anthony G ^a  

^a MCGILL UNIVERSITY   (Canada)

^b UNIVERSITÉ DE MONTRÉAL   (Canada)

Author keywords

Head and neck; Inflammation; Mortality; Neutrophil to lymphocyte ratio; Platelet to lymphocyte ratio; Recurrence; Squamous cell cancer

Indexed keywords

TUMOR MARKER; BIOLOGICAL MARKER;

ADULT; ARTICLE; CANCER CLASSIFICATION; CANCER DIAGNOSIS; CANCER MORTALITY; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER STAGING; CANCER SURVIVAL; CONTROLLED STUDY; FEMALE; HEAD AND NECK SQUAMOUS CELL CARCINOMA; HUMAN; MAJOR CLINICAL STUDY; MALE; NEUTROPHIL LYMPHOCYTE RATIO; PLATELET LYMPHOCYTE RATIO; PREDICTION; RECURRENCE RISK; RETROSPECTIVE STUDY; AGED; BLOOD; CARCINOMA, SQUAMOUS CELL; DISEASE FREE SURVIVAL; HEAD AND NECK NEOPLASMS; LYMPHOCYTE COUNT; MIDDLE AGED; MORTALITY; NEOPLASM RECURRENCE, LOCAL; NEUTROPHIL; PREDICTIVE VALUE; SURVIVAL RATE; THROMBOCYTE COUNT; VERY ELDERLY;

AGED; AGED, 80 AND OVER; BIOLOGICAL MARKERS; CARCINOMA, SQUAMOUS CELL; DISEASE-FREE SURVIVAL; FEMALE; HEAD AND NECK NEOPLASMS; HUMANS; LYMPHOCYTE COUNT; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NEUTROPHILS; PLATELET COUNT; PREDICTIVE VALUE OF TESTS; RETROSPECTIVE STUDIES; SURVIVAL RATE;

EID: 84918785710     PISSN: 10433074     EISSN: 10970347     Source Type: Journal    
DOI: 10.1002/hed.23567     Document Type: Article

References (38)

1. Pryor DI, Solomon B, Porceddu SV. The emerging era of personalized therapy in squamous cell carcinoma of the head and neck. Asia Pac J Clin Oncol 2011;7:236-251.
2. Chang SS, Califano J. Current status of biomarkers in head and neck cancer. J Surg Oncol 2008;97:640-643.
3. Dasgupta S, Koch R, Westra WH, et al. Mitochondrial DNA mutation in normal margins and tumors of recurrent head and neck squamous cell carcinoma patients. Cancer Prev Res (Phila) 2010;3:1205-1211.
4. Lee JM, Turini M, Botteman MF, Stephens JM, Pashos CL. Economic burden of head and neck cancer. A literature review. Eur J Health Econ 2004; 5:70-80.
5. Mantovani A, Allavena P, Sica A, Balkwill F. Cancer-related inflammation. Nature 2008;454:436-444.
6. Bang KM, Laing CA. Lymphocytopenia in high cancer risk population: evidence in automobile pattern makers. Cancer Lett 1986;30:311-314.
7. Monreal M, Fernandez-Llamazares J, Piñol M, et al. Platelet count and survival in patients with colorectal cancer-a preliminary study. Thromb Haemost 1998;79:916-918.
8. Trellakis S, Farjah H, Bruderek K, et al. Peripheral blood neutrophil granu-locytes from patients with head and neck squamous cell carcinoma functionally differ from their counterparts in healthy donors. Int J Immunopathol Pharmacol 2011;24:683-693.
9. Smith RA, Bosonnet L, Raraty M, et al. Preoperative platelet-lymphocyte ratio is an independent significant prognostic marker in resected pancreatic ductal adenocarcinoma. Am J Surg 2009;197:466-472.
10. Halazun KJ, Aldoori A, Malik HZ, et al. Elevated preoperative neutrophil to lymphocyte ratio predicts survival following hepatic resection for colo-rectal liver metastases. Eur J Surg Oncol 2008;34:55-60.
11. Sarraf KM, Belcher E, Raevsky E, Nicholson AG, Goldstraw P, Lim E. Neutrophil/lymphocyte ratio and its association with survival after complete resection in non-small cell lung cancer. J Thorac Cardiovasc Surg 2009;137:425-428.
12. Cho H, Hur HW, Kim SW, et al. Pre-treatment neutrophil to lymphocyte ratio is elevated in epithelial ovarian cancer and predicts survival after treatment. Cancer Immunol Immunother 2009;58:15-23.
13. Keleş S, Segal MR. Residual-based tree-structured survival analysis. Stat Med 2002;21:313-326.
14. Therneau TM, Atkinson B. CRAN-Package rpart. Available at: http://www.CRAN.R-project.org/package5rpart. Accessed December 1, 2013.
15. Balkwill F, Mantovani A. Inflammation and cancer: back to Virchow? Lancet 2001;357:539-545.
16. Balkwill FR, Mantovani A. Cancer-related inflammation: common themes and therapeutic opportunities. Semin Cancer Biol 2012;22:33-40.
17. Jabłonska E, Garley M, Jabłonski J. The expressions of intrinsic and extrinsic apoptotic pathway proteins in neutrophils of oral cavity cancer patients: a preliminary study. Arch Immunol Ther Exp (Warsz) 2009;57:229-234.
18. Andreu P, Johansson M, Affara NI, et al. FcR gamma activation regulates inflammation-associated squamous carcinogenesis. Cancer Cell 2010;17: 121-134.
19. DeNardo DG, Johansson M, Coussens LM. Immune cells as mediators of solid tumor metastasis. Cancer Metastasis Rev 2008;27:11-18.
20. Borrello MG, Alberti L, Fischer A, et al. Induction of a proinflammatory program in normal human thyrocytes by the RET/PTC1 oncogene. Proc Natl Acad Sci USA 2005;102:14825-14830.
21. Balkwill F. Tumour necrosis factor and cancer. Nat Rev Cancer 2009;9: 361-371.
22. Xia J, Chen N, Hong Y, et al. Expressions of CXCL12/CXCR4 in oral pre-malignant and malignant lesions. Mediators Inflamm 2012;2012:516395.
23. Hoffmann TK, Dworacki G, Tsukihiro T, et al. Spontaneous apoptosis of circulating T lymphocytes in patients with head and neck cancer and its clinical importance. Clin Cancer Res 2002;8:2553-2562.
24. Kuss I, Hathaway B, Ferris RL, Gooding W, Whiteside TL. Decreased absolute counts of T lymphocyte subsets and their relation to disease in squamous cell carcinoma of the head and neck. Clin Cancer Res 2004;10: 3755-3762.
25. Cassatella MA. The production of cytokines by polymorphonuclear neutrophils. Immunol Today 1995;16:21-26.
26. Bergers G, Brekken R, McMahon G, et al. Matrix metalloproteinase-9 triggers the angiogenic switch during carcinogenesis. Nat Cell Biol 2000;2: 737-744.
27. Zhang H, Xu L, Xiao D, et al. Upregulation of neutrophil gelatinase-associated lipocalin in oesophageal squamous cell carcinoma: significant correlation with cell differentiation and tumour invasion. J Clin Pathol 2007;60:555-561.
28. Lin EY, Pollard JW. Tumor-associated macrophages press the angiogenic switch in breast cancer. Cancer Res 2007;67:5064-5066.
29. Estrov Z, Talpaz M, Mavligit G, et al. Elevated plasma thrombopoietic activity in patients with metastatic cancer-related thrombocytosis. Am J Med 1995;98:551-558.
30. Naugler WE, Karin M. The wolf in sheep's clothing: the role of interleukin-6 in immunity, inflammation and cancer. Trends Mol Med 2008;14:109-119.
31. Ancrile B, Lim KH, Counter CM. Oncogenic Ras-induced secretion of IL6 is required for tumorigenesis. Genes Dev 2007;21:1714-1719.
32. Shain KH, Yarde DN, Meads MB, et al. Beta1 integrin adhesion enhances IL-6-mediated STAT3 signaling in myeloma cells: implications for micro-environment influence on tumor survival and proliferation. Cancer Res 2009;69:1009-1015.
33. Naugler WE, Sakurai T, Kim S, et al. Gender disparity in liver cancer due to sex differences in MyD88-dependent IL-6 production. Science 2007; 317:121-124.
34. Kitayama J, Yasuda K, Kawai K, Sunami E, Nagawa H. Circulating lymphocyte is an important determinant of the effectiveness of preoperative radiotherapy in advanced rectal cancer. BMC Cancer 2011;11:64.
35. Sato H, Tsubosa Y, Kawano T. Correlation between the pretherapeutic neu-trophil to lymphocyte ratio and the pathologic response to neoadjuvant chemotherapy in patients with advanced esophageal cancer. World J Surg 2012;36:617-622.
36. Liu H, Liu G, Bao Q, et al. The baseline ratio of neutrophils to lymphocytes is associated with patient prognosis in rectal carcinoma. J Gastrointest Cancer 2010;41:116-120.
37. Yamanaka T, Matsumoto S, Teramukai S, Ishiwata R, Nagai Y, Fukushima M. The baseline ratio of neutrophils to lymphocytes is associated with patient prognosis in advanced gastric cancer. Oncology 2007;73: 215-220.
38. An X, Ding PR, Li YH, et al. Elevated neutrophil to lymphocyte ratio predicts survival in advanced pancreatic cancer. Biomarkers 2010; 15: 516-522.